Citigroup
ADMA icon

Citigroup’s ADMA Biologics ADMA Stock Holding History

Citigroup’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,600
Closed -$742K – 6015
2025
Q3 		$742K Hold
50,600
– – ﹤0.01% 3360
2025
Q2 		$921K Buy
+50,600
New +$1.03M ﹤0.01% 3242

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup's ADMA Position: Q2 2026 in Review

Citigroup increased its ADMA Biologics (ADMA) stake by 600% in Q2 2026, buying an estimated $3.78M and bringing the position to 484,273 shares worth $4.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Citigroup first reported a position in ADMA in Q4 2014 and has held it in 38 quarters since. The position peaked at $19.9M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Citigroup held 484,273 shares of ADMA Biologics worth $4.05M as of Q2 2026.
  • Citigroup bought 415,064 ADMA Biologics shares in Q2 2026, an estimated $3.78M.
  • ADMA Biologics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2326 holding.
  • Citigroup first reported a position in ADMA Biologics in Q4 2014 and has held it in 38 quarters since.
  • Citigroup's ADMA Biologics position peaked at $19.9M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.